OKYO Pharma (OKYO Pharma) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2023)

View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. OKYO Pharma's annualized Gross Profit for the quarter that ended in Mar. 2023 was $0.00 Mil. OKYO Pharma's average Total Assets over the quarter that ended in Mar. 2023 was $3.49 Mil. Therefore, OKYO Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2023 was 0.00%.

OKYO Pharma Gross-Profit-to-Asset % Historical Data

The historical data trend for OKYO Pharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OKYO Pharma Gross-Profit-to-Asset % Chart

OKYO Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

OKYO Pharma Semi-Annual Data
	Sep13	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of OKYO Pharma's Gross-Profit-to-Asset %

For the Biotechnology subindustry, OKYO Pharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OKYO Pharma's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OKYO Pharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where OKYO Pharma's Gross-Profit-to-Asset % falls into.

OKYO Pharma Gross-Profit-to-Asset % Calculation

OKYO Pharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Mar. 2023 )	/	( (Total Assets (A: Mar. 2022 )	+	Total Assets (A: Mar. 2023 ))	/ count )
	=	0	/	( (4.301	+	5.204)	/ 2 )
	=	0	/	4.7525
	=	0.00 %

OKYO Pharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2023 )	/	( (Total Assets (Q: Sep. 2022 )	+	Total Assets (Q: Mar. 2023 ))	/ count )
	=	0	/	( (1.774	+	5.204)	/ 2 )
	=	0	/	3.489
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Mar. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

OKYO Pharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of OKYO Pharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

OKYO Pharma (OKYO Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

OK10:Germany

Address

14/15 Conduit St, Floor 4, London, GBR, W1S 2XJ

Website

https://www.okyopharma.com

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

Executives

John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob	director, officer: Chief Executive Officer
Gabriele M Cerrone	director, 10 percent owner, officer: Executive Chairman	265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer	director	C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon	director	PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah	officer: Chief Financial Officer	55 PARK LANE, LONDON X0 W1K 1NA